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Abstract  Severe  hemoptysis  is  life-threatening  to  patients  because  of  the  asphyxia  it  causes.
The diagnosis  and  treatment  are  therefore  urgent  and  chest  imaging  is  essential.  Multidetector
CT-angiography  provides  an  exhaustive  non-invasive  assessment  which  includes  localization,
mechanisms,  causes  and  severity  of  the  hemoptysis.  It  is  an  invaluable  step  in  preparation
for endovascular  treatment  which  is  the  ﬁrst  line  invasive  therapy,  particularly  with  bronchial
arteriography  embolization  in  the  majority  of  cases  (over  90%)  and  erosion  or  rupture  of  the
pulmonary artery  in  less  than  10%  of  cases.  Hemoptysis  control  is  achieved  in  65  to  92%  of  cases
depending  on  the  cause.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Hemoptysis  is  the  exteriorization  of  red  aerated  blood  from  the  mouth  following  a  cough
originating  from  below  the  glottis.  It  represents  blood  from  the  thoracic  vascular  sec-
tor  passing  into  the  respiratory  sector.  Hemoptysis  is  a common  symptom  in  respiratory
medicine.  It  accounts  for  10  to  15%  of  the  reasons  for  consultation  in  hospital  respiratory
department  and  is  a  warning  signal  for  investigation  into  its  cause  [1,2]. Severe  hemoptysis
(SH)  is  life-threatening  and  has  a  mortality  rate  of  over  50%  without  control  of  the  bleeding
[3,4].  It  requires  rapid  and  simultaneous  management  for  both  diagnostic  (mechanism  and
cause)  and  therapeutic  [5]  purposes.  Endovascular  management,  especially  embolization
of  the  bronchial  arteries,  is  now  the  1st  line  treatment  [5]  to  control  the  bleeding.  The
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ndications  for  endovascular  treatment  are  unequivocal  in
emoptysis  which  is  causing  concern  because  of  its  volume
over  200  mL/24—48  h),  its  consequences  on  the  respira-
ory  system  (acute  respiratory  failure)  or  if  the  mechanism
s  potentially  life-threatening  (erosion  of  the  pulmonary
rtery)  [6].
The  physician  (ideally  the  intensive  care  physician)  faced
ith  a  case  of  SH  should  ask  him/herself  ﬁve  questions:
s  this  actually  hemoptysis?  How  severe  is  it?  What  is  the
ite?  What  is  its  cause  and  most  likely  mechanism?  What
reatment  should  be  given?  Multidetector  CT-angiography
MDCTA)  can  answer  a  number  of  these  questions  (Fig.  1)
nd  is  essential  for  the  radiologist  before  considering  inter-
entional  radiology  [7,8].
he use of CT angiography in severe
emoptysis
maging technique
he  investigation  should  be  performed  in  deep  inspiration  if
ossible,  failing  which  it  should  be  performed  in  free  res-
iration  [9].  All  of  the  intrathoracic  blood  vessels  should
e  enhanced  using  a  contrast  injection  rate  (at  a  concen-
ration  of  300  mg  of  iodine/mL)  of  3.5  to  4  mL/sec  with
 total  volume  of  90  mL.  Image  acquisition  is  triggered  by
 region  of  interest  (ROI)  in  the  descending  aorta  from
00  Hounsﬁeld  Units  for  16-row  CT-scan  and  150  HU  for  a
igher  row  CT-scan.  Coverage  should  begin  from  the  lung
pices  (C5-C6)  to  the  hilum  of  the  kidneys  (L1-L2),  from  the
upra-aortic  vessels  to  the  origin  of  the  inferior  diaphrag-
atic  arteries.  It  is  recommended  that  images  be  started
t  the  base  of  the  cranium  in  patients  with  a  past  his-
ory  of  neck  surgery  or  radiotherapy  for  a  nasopharyngeal
ancer.
igure 1. Interpretation algorithm and expected results of mul-
idetector CT-angiography. MDCTA: multidetector CT-angiography;
IP: maximum intensity projection; VRT: volume rendering
echnique; PA: pulmonary artery; BA: bronchial artery; NBSA: non-
ronchial systemic artery.
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onﬁrmation of the hemoptysis
n  the  majority  of  cases,  the  clinical  enquiry  will  establish
he  origin  of  red  blood  coming  from  the  mouth.  Occasionally,
 diagnosis  is  uncertain  and  MDCTA  can  therefore  demon-
trates  a  cause  and/or  signs  of  alveolar  or  bronchial  ﬂooding
ith  intraluminal  clots.
everity of the bleeding
n  terms  of  severity,  the  volume  of  hemoptysis  and  respira-
ory  consequences  can  clinically  identify  the  majority  of  SH
6].  If  the  clinical  enquiry  however  is  unreliable,  MDCTA  may
gain  offer  assistance  [7].
We  have  shown  that  the  extent  of  parenchymal  involve-
ent  on  CT  correlates  with  the  magnitude  of  the  bleed
nd  with  clinical  severity.  Involvement  of  more  than  3  lobes
s  usually  associated  with  exteriorized  bleeding  of  over
00  mL/24—48  h  and  requires  more  interventionist  treat-
ent  [10]  even  if  the  patient  has  not  coughed  up  a  large
olume  of  blood  (Fig.  2).
ite of the bleed
ateralization  (the  bleeding  side)  and  precise  localization  of
he  hemoptysis  are  essential  for  treatment.  When  hemopt-
sis  is  causing  asphyxia,  simple  selective  protection  of  the
espiratory  tract  can  only  be  performed  when  the  side  of  the
leeding  is  known.  Similarly,  some  embolization  decisions  in
ituations  at  high  risk  of  complication  can  only  be  consid-
red  if  the  side  of  the  hemoptysis  is  known  with  certainty.
he  decision  to  perform  surgery  to  stop  bleeds  can  also  only
e  made  when  there  is  certainty  as  to  the  lobe  that  is  to  be
xcised.
The  bleed  is  localized  from  the  parenchymal  window
nvestigation  that  seeks  to  identify  aground  glass  opacity
r  alveolar  consolidation  (Fig.  3a,b).  This  abnormality  is
f  high  localizing  value  [10—12].  The  presence  of  several
reas  of  ground  glass  opacities  and/or  alveolar  consolida-
ion  with  a  relatively  unaffected  subpleural  area  should
uggest  the  possibility  of  intra-alveolar  hemorrhage.  If  a
round  glass  opacity  image  is  present  in  the  bases  together
ith  an  alveolar  consolidation  in  the  upper  part  of  the
ung  (Fig.  2),  the  site  of  the  bleeding  is  the  highest
art  and  the  other  abnormalities  are  due  to  positional
ooding  [12].
Some  signs  reﬂect  the  cause  (bronchiectasis,  cavitation
r  pulmonary  artery  pseudoaneurysm)  or  consequence  of
he  bleeding  (endobronchial  clot)  and  have  lower  localizing
alue.
Lung  consolidation  with  necrosis  or  cavitation  associated
ith  the  appearance  of  a pulmonary  artery  pseudoaneurysm
an  uncommon  situation)  indicates  a bleed  originating  from
he  pulmonary  artery  (Fig.  4).
The  topographic  diagnostic  yield  of  MDCTA  compared  to
linical  assessment  at  the  patient’s  bedside  (including  the
linical  enquiry,  clinical  examination,  chest  radiography  and
ronchoscopy)  is  similar  and  in  the  region  of  80%  [7].  As  a
esult,  in  our  view,  bronchoscopy  can  be  delayed.
Bronchoscopy  is  no  longer  the  ﬁrst  line  investigation  to
ocate  the  bleeding  and  is  reserved  for  diffuse  or  bilateral
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ed alveolar changes (asterisk) surrounded by ground glass opacities in
the lung bases: nodular ground glass opacities (asterisk) indicating the
Boxed  text  1:  Major  causes  of  hemoptysis.
Bronchiectasis,  tumors,  tuberculosis  (acute  and
late  complications)  and  cryptogenic  causes  account
for  over  80%  of  the  causes  of  hemoptysis.
A  —  Tumors
Malignant:  lung  cancer  metastases
Benign:  carcinoid  tumor
B —  Bronchiectasis
C  —  Infections
Tuberculosis,  atypical  Mycobacter  infection
Chronic  pulmonary  aspergillosis
Invasive  aspergillosis
Necrotizing  pneumonias
Lung  abscesses
D  —  Vascular
Pulmonary  arterial  aneurysms
Pulmonary  sequestration
Arteriovenous  malformation
Traumatic  pulmonary  artery  pseudoaneurysm  (Swan
Ganz)
E  —  Vasculitis
Granulomatosis  with  polyangiitis  (formerly  Wegener’s
disease)
Behc¸et’s  disease  and  Hughes-Stovin  syndrome
Takayashu’s  disease
F  —  Trauma
Post-traumatic  hematoma
Post-traumatic  ﬁstula
Pulmonary  erosion  from  a rib  fragment
G  —  Cardiovascular  abnormalities
Eisenmenger’s  syndrome
Mitral  stenosis
Aortobronchial  ﬁstula
H  —  Bronchial  circulation  abnormality
Dieulafoy’s  syndromeFigure 2. Severity of hemoptysis. a: axial CT-scan image: localiz
the lingula, locating the bleeding to this area; b: axial CT-scan in 
extent of the hemoptysis and ﬂooding of the lower lobe.
diseases  for  which  MDCTA  is  not  accurate  to  locate  the  bleed-
ing  site.  The  majority  of  patients  will  undergo  bronchoscopy
after  the  episode  of  bleeding,  4  to  6  days  after  endovascu-
lar  treatment.  In  this  situation,  the  yield  of  bronchoscopy  is
higher  as  it  examines  a  clean  bronchial  tree  (distant  to  the
bleeding  and  without  clots)  and  allows  biopsies  to  be  taken
in  a  more  settled  environment  after  embolization.
Cause of the bleeding
Hemoptysis  has  many  causes  (Boxed  text  1).  More  than  2/3
of  the  cases  of  hemoptysis  in  France  are  due  to  three  causes:
active  tuberculosis  (Fig.  5)  or  complications  of  old  tubercu-
losis  (Fig.  6),  bronchiectasis  and  lung  cancer  (Fig.  7a—c).
Cryptogenic  hemoptysis  accounts  for  20  to  30%  of  cases  and
is  deﬁned  as  hemoptysis  with  no  cause  found  during  the  hos-
pitalization  and  a  negative  assessment  at  3  months  including
CT-scan  and  bronchoscopy  (Fig.  8).
Mechanism of the bleeding
The  two  major  mechanisms  responsible  for  hemoptysis  are
the  systemic  arteries  (bronchial  arteries  and  non-bronchial
systemic  arteries)  in  90%  of  cases  and  the  pulmonary  arteries
in  under  10%  of  cases.  MDCTA  signs  of  systemic  bleed-
ing  are  indirect,  whereas  the  MDCTA  of  pulmonary  arterial
involvement  are  direct  [12].  When  a  MDCTA  is  requested  for
hemoptysis,  bleeding  from  the  pulmonary  artery  must  ﬁrstly
be  excluded,  looking  for  direct  signs,  although  in  some  cases
both  mechanisms  may  be  involved.
Hemoptysis arising from the pulmonary artery
Less  than  10%  of  all  cases  of  hemoptysis  originate  from
the  pulmonary  artery.  The  mechanism  of  this  type  of
bleeding  depends  on  the  cause,  and  may  be  traumatic
(Swan-Ganz  catheter),  inﬂammatory  (Behc¸et’s  disease
or  Hughes-Stovin’s  syndrome),  neoplastic  (tumor  necro-
sis  and  when  the  pulmonary  artery  is  not  encased  in
solid  tumor),  and  infection.  The  most  common  causes
Bronchial  artery  hemangioma
I  —  Cryptogenic  (no  cause  found)
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Figure 3. Hemoptysis associated with bronchiectasis. Forty-three-year-old female patient with no particular past history, transferred
to intensive care for massive hemoptysis about 350 mL on one time. a: axial CT-scan image in the parenchymal window focused on the
right middle lobe bronchus. Ground glass opacities (asterisk) with bronchiectasis fully ﬁlled with blood clots (black arrows); b: sagittal
reconstruction image in the parenchymal window showing the bronchus fully ﬁlled with clots (black arrows) and distal consolidation in
t r lob
i rom 
a
o
a
t
ahe right middle lobe. Note the increased density in the right lowe
nfracarenal region. Bronchial vessel with an atypical origin arising f
fter embolization with particles and occlusion with coils (f).f  infections  are  predominantly  tuberculosis  (Rasmussen
neurysm),  necrotic  infectious  pneumonias  and  other  infec-
ions  involving  parenchymal  necrosis  such  as  invasive
spergillosis.
d
m
ae; c, d: axial CT-scan images passing through the aortic arch and
the aortic arch (arrows); e, f: bronchial angiography before (e) andThe  MDCTA  signs  of  pulmonary  arterial  involvement
epend  on  the  cause  [13].  In  systemic  disease  with  pul-
onary  artery  aneurysms,  the  pulmonary  artery  aneurysm
t  the  origin  of  the  bleeding  is  present  within  an  area  of
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Figure 4. Necrotic pneumonia with a pulmonary artery pseudo-aneurysm. a, b: six mm maximum intensity projection, axial (a) and
 of th
pseudcoronal (b) views showing lung consolidation of the ventral segment
a branch of the pulmonary artery representing a pulmonary artery 
lung  consolidation  or  ground  glass  opacity  (Fig.  4).  This
aneurysm  requires  emergency  treatment.  The  majority  of
other  pulmonary  artery  aneurysms  respond  well  to  appro-
priate  medical  therapy.
b
c
m
Figure 5. Hemoptysis and active tuberculosis. Nineteen-year-old fema
sis. Clinical enquiry assessed the hemoptysis volume as being over 250 mL 
lung cavities in the left upper lobe with adjacent nodules, lung consoli
b: axial CT-scan passing through the apex conﬁrming the CXR ﬁndings: c
view passing through the main trunk of the pulmonary artery: bilateral h
lymphadenopathy; d: axial CT-scan showing the tree-in-bud appearance 
diagnosis was conﬁrmed to be active bacillary pulmonary tuberculosis r
arteries achieved immediate control without recurrence.e culmen with necrosis (black arrow) and ectasia (white arrow) of
o-aneurysm.
In  infectious  disease,  the  main  sign  is  necrosis  which  can
e  identiﬁed  as  a  hypodense  area  within  lung  parenchymal
onsolidation  which  is  enhanced  by  the  iodinated  contrast
edia.  Late  phase  CT  images  or  enhanced  images  can
le patient presenting to the emergency department with hemopty-
during the last 24 hours. a: postero-anterior chest radiograph (CXR):
dation in the lingula and right axillary micronodular appearances;
avernous appearance with nodules in the culmen; c: axial CT-scan
ilar lymphadenopathy predominantly on the left and infracarenal
(branch nodules) indicating bronchiolar spread of the disease. The
esponsible for hemoptysis for which embolization of the bronchial
780  A.  Khalil  et  al.
Figure 6. Hemoptysis and late complications of tuberculosis. Fifty-three-year-old man hospitalized for hemoptysis of 300 mL over the
previous 48 hours. a: postero-anterior chest radiograph: aerated atelectasis of the culmen with bronchiectasis(arrow) and raised left main
bronchus; b: CT-scan image passing through the apices: traction bronchiectasis combined with adjacent lung consolidation and a ground
glass opacity indicating the site of the hemoptysis; c: CT-scan image passing through the bases: nodules of increased density with ground
glass opacity in the left lower lobe indicating the extent of the hemoptysis and ﬂooding from the culmen; d: coronal reconstruction: good
correlation with the chest radiograph. Raised left ﬁssure with bronchiectasis in the culmen and increased ground glass opacity. A bronchial
a as c
i
i
t
m
m
c
b
H
s
B
a
g
a
r
[
t
d
i
o
o
t
o
d
(
o
a
c
7
o
r
5
a
(
trteriography with embolization (in addition to antibiotic therapy) w
mprove  visibility  of  the  hypodense  area.  The  second  sign
s  a  pseudoaneurysm  within  the  hypodense  area.  Investiga-
ion  for  a  pseudoaneurysm  is  performed  on  5  to  8  mm  thick
aximal  intensity  projection  (MIP)  reconstructions  in  the
ediastinal  window  in  all  three  spatial  planes.  A  less  spe-
iﬁc  sign  is  the  presence  of  a  pulmonary  artery  with  irregular
orders  in  the  wall  of  the  necrosis.
emoptysis of systemic origin and mapping of
ystemic arteries
y  excluding  a  pulmonary  arterial  mechanism,  MDCTA  allows
 conclusion  to  be  drawn  that  the  hemoptysis  has  its  ori-
in  in  a  systemic  artery.  MDCTA  visualizes  the  bronchial
rteries  (BA)  and  the  non-bronchial  systemic  arteries  (NBSA)
esponsible  for  the  bleeding.  In  addition,  Remy-Jardin  et  al.
8]  have  shown  that  MDCTA  is  more  accurate  than  conven-
ional  angiography  in  identifying  the  bronchial  arteries.  This
ifference  is  explained  by  anatomical  variants  and  catheter-
zation  difﬁculties  associated  with  patient  age  because
t
r
[arried out with no recurrence after a follow-up period of 6 months.
f  atheromatous  plaques.  We  have  compared  two  groups
f  patients  who  underwent  systemic  arterial  emboliza-
ion  or  attempted  embolization  before  and  after  the  era
f  MDCTA;  we  included  200  patients  in  each  group  and
ivided  the  cohorts  into  3  groups  according  to  patient  age
under  50  years  old,  50  to  70  years  old  and  over  70  years
ld)  and  compared  the  catheterization  failure  rate  by
ge  band  in  both  cohorts  (with  and  without  MDCTA).  The
atheterization  failure  rates  in  the  group  of  patients  over
0  years  old  were  36.6%  and  14.6%  in  the  cohorts  with-
ut  and  with  MDCTA  respectively.  By  expressing  the  failure
ate  as  a  ratio  to  the  age  band  of  patients  between
0  and  70  years  old,  we  found  that  the  failure  rate  was
lmost  stable  when  the  procedure  was  preceded  by  MDCTA
14.6  compared  to  12%),  whereas  it  increased  by  a  fac-
or  of  almost  3.5  if  MDCTA  was  not  used  (36.6  compared
o  10.2%).
The  use  of  Volume  rendering  technic  (VRT)  is  more  accu-
ate  (Fig.  7c) than  axial  images  to  detect  ectopic  arteries
9,14]  and  their  path  in  the  mediastinum.
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Figure 7. Left lower lobe non-small cell lung cancer (squamous cell) with 40 mL/day hemoptysis for several weeks. The frequency and
volume of the hemoptysis have increased recently. a: axial CT-scan image: showing stenosis of the pulmonary artery (arrow) by the tumor
and hypertrophy of the left bronchial artery (arrowheads); b: coronal maximal intensity projection reconstruction of 12 mm  thick slab
showing a left hilar pulmonary mass surrounding the pulmonary artery (white arrow) and a hypertrophy of a broncho-intercostal trunk
(black arrow) giving rise to a collateral right bronchial artery (arrowheads); c: coronal volume rendered technical reconstruction showing
the right broncho-intercostal trunk with its right bronchial artery (arrowheads) and in particular the origin of a common right-left bronchial
trunk (CRLBT; arrow) giving rise to the left vascularization and the right inferior bronchial artery; d: CRLBT angiogram showing left hilar
hypervascularization with no systemic-pulmonary shunt; e: intermediary RLCBT repeat angiogram showing near complete devascularization
of the tumor; f: RLCBT angiogram after hyper-selective catheterization with a Progreat 2.4-F (Terumo) microcatheter: persistent slight tumor
parencymography. Further embolization with Embozene® 700 particles (CeloNova); g: repeat angiogram after occluding the left bronchial
artery of the CRLBT with a Micro-Nester® 0.18 coil (COOK): permanent occlusion of the bronchial artery and opaciﬁcation of a small superior
collateral vessel (arrow). Because of the persistent hemoptyses with fresh blood in the region of 50 mL/day, the decision was taken to
repeat the procedure; h: CRLBT angiogram showing vascularization with a neoplastic appearance at the start of the small collateral which
was left patent in the ﬁrst embolization; i: repeat after embolization with Onyx® HD18: satisfactory progression of the material with the
microcatheter at the tip of the 5-F catheter. The hemoptysis stopped immediately.
782  A.  Khalil  et  al.
Figure 8. Cryptogenic hemoptysis. Forty-ﬁve-year-old man presenting to respiratory department with hemoptysis. Clinical enquiry
assessed the hemoptysis as being 100 mL/24 h. a: axial CT-scan image in the parenchymal window showing an area of increased den-
sity with focal ground glass opacity (asterisk) localizing the bleeding; b, c: axial CT-scan image in the mediastinal window: nodular or
linear enhancement in the mediastinum representing the bronchial vessels in their mediastinal path; d: frontal reconstruction image in the
mediastinal window showing the left bronchial trunk (black arrow) and bronchial artery (white arrowhead) of the right broncho-intercostal
trunk; e: coronal image with volume rendered technical reconstruction showing the left bronchial artery (black arrow), the right broncho-
intercostal trunk (white arrow) and the right bronchial artery (white arrowheads) of this trunk; f: axial CT-scan image 1 month later showing
disappearance of the increased density of ground glass appearance. Bronchoscopy, bacteriology samples and the immunology assessment
were negative. The diagnosis made was that of cryptogenic hemoptysis (without cause).
•
•
•
•
•
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Currently,  the  identiﬁcation  of  the  middle  anterior  spinal
artery  of  the  high  thoracic  spinal  cord  is  only  possible  with
conventional  angiography  (Fig.  9a—c).
The  contribution  to  the  bleeding  from  NBSA  should  be
considered  in  chronic  disease  with  a  pleural  symphysis.  Yoon
et  al.  showed  that  CT-scan  offered  excellent  sensitivity  and
speciﬁcity  and  had  a  high  diagnostic  value  in  detecting  NBSA
[15,16].  The  NBSA  may  contribute  to  hypervascularization
and  bleeding  in  chronic  lung  disease  with  pleural  involve-
ment.
Contribution  from  NBSA  to  the  hypervascularization  is
unequivocal  if  systemic  vessels  pass  through  pleura  that  are
over  3  mm  thick.
The  NBSA  most  often  found  are:
• the  intercostal  arteries  in  posterior  disease;
h
C
i
Figure 9. Median anterior spinal artery at the cervicothoracic junctio
right superior bronchial artery; b, c: angiogram of the same artery ma
cervicothoracic spine and showing a small narrow vessel leading towards 
lateralized to the right because of slight rotation of the patient with respe
the cervicothoracic region of the spinal cord; d: use of a microcatheter w
2 mm in diameter and 7 cm long). Particles are formerly contra-indicated 
as a result of reﬂux from the median anterior spinal artery.783
branches  of  the  subclavian  arteries  in  the  apices;
the  internal  thoracic  arteries  in  the  anterosuperior  seg-
ments;
the  triangular  ligament  arteries  in  the  bases  and  parame-
diastinal  region;
the  inferior  diaphragmatic  arteries  in  the  bases;
the  coronary  arteries  in  some  diseases.
ndovascular treatment of severe
emoptysis
urrently,  this  treatment  can  only  be  considered  after  an
nitial  MDCTA  assessment  and  in  close  collaboration  with
n. a: angiogram of a right broncho-intercostal trunk showing the
gniﬁed (subtracted ‘‘b’’ and unsubtracted ‘‘c’’) centering on the
the middle with a ‘‘hairpin’’ shape. This structure, which is slightly
ct to the X-ray beam, is the median anterior spinal artery supplying
ith occlusion of the trunk using 3-F Micro-Nester® 0.18 coils (COOK;
in this situation because of the large risk of accidental embolization
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ntensive  care  or  respiratory  physicians  and  surgical  team
or  overall  management  of  the  disease.
In  our  center,  the  indication  for  this  treatment
Fig.  10)  is  based  on  the  volume  of  the  hemoptysis
over  200  mL/24—48  h),  repercussions  on  oxygenation  (acute
espiratory  failure)  and  on  any  pulmonary  artery  dam-
ge.  Below  50  mL/24—48  h,  endovascular  management  is  not
ndicated  and  between  50  and  200  mL/24—48  h,  the  indi-
ation  depends  on  the  patient’s  underlying  condition  (poor
espiratory  reserve  in  patients  with  chronic  respiratory  fail-
re)  or  causes  such  as  aspergilloma  with  a  high  risk  of
ecurrence  as  massive  hemoptysis.
echniques, approaches and embolization
aterials
mbolization of systemic arteries (BA and
BSA)
n  the  majority  of  situations,  the  approach  is  via  the
ight  femoral  artery  after  inserting  a  5-F  introducer.  We
refer  to  use  long  5-F  introducers  (45  cm)  in  patients
ver  70  years  old  or  in  those  with  tortuous  atheromatous
rteries  which  makes  navigation  and  catheterization  more
traightforward.
The  two  catheters  used  on  ﬁrst  line  are  the  JL4  (left
oronary  catheter)  and  the  spinal  catheter.  Others  may  be
equired  such  as  the  left  bronchial  catheter,  an  AL1  or  AL2
t
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igure 10. Chart indicating the management of life-threatening hem
hest-X-ray (CXR), and a multidetector CT-angiography (MDCTA) ± bronc
ronchial arteriography with embolization (BAE) or pulmonary artery va
reatment (BAE or PAVO) or medical treatment depends on the cause (a
nderlying diseases (chronic respiratory failure with a risk of major respiA.  Khalil  et  al.
atheter  and  internal  thoracic  artery  catheter,  etc.  The  two
eft  bronchial  and  left  coronary  catheters  can  ‘‘scrape’’  the
oor  of  the  aortic  arch  and  catheterize  the  bronchial  arter-
es  arising  from  it.
By referring  to  MDCTA  ﬁndings,  arteries  feeding  the
leeding  area  are  catheterized  and  an  angiography  series
s  then  performed.
A microcatheter  is  recommended  for  safer  embolization,
lthough  the  risk  of  spasm  and  dissection  of  the  bronchial
rteries  during  catheterization  with  a microcatheter  is
igher,  which  prevent  optimal  embolization.  If  gentle  risk-
ree  embolization  from  the  ostium  of  systemic  arteries  is
ossible  (Fig.  7d—g),  we  recommend  starting  the  emboliza-
ion  using  the  5-F  catheter.  Early  and  repeated  checks  are
equired  in  order  to  avoid  reﬂux  of  the  embolization  materi-
ls  and  to  detect  hazardous  anastamoses  as  early  as  possible.
hese  anastamoses  may  be  unmasked  when  the  hypervas-
ularization  is  reduced  during  ostial  embolization  by  the
atheter,  or  more  distally  with  the  microcatheter.
The  ﬁrst  line  embolization  materials  are  particles  that
re  currently  available  in  many  sizes  on  the  market,  each
f  which  has  slightly  different  physical  features.  In  our  cen-
er,  we  use  Embozene® 700  to  1300  microns,  depending  on
he  hypervascularization,  systemic  to  pulmonary  shunts  and
he  lumen  size  of  the  catheter  or  micro-catheter.  For  a
arge  systemic-pulmonary  shunt,  the  use  of  a  large  particle
ize  is  required.  Coils  can  be  used,  however,  the  opera-
or  remembers  that  proximal  occlusion  (mediastinal  and
optysis. The initial assessment includes a clinical assessment, a
hoscopy. The ﬁrst line of treatment is interventional radiology or
so-occlusion (PAVO). * In this situation, the indication for invasive
spergilloma with risk of recurrence by massive hemoptysis) or the
ratory impairment with a small amount of hemoptysis recurrence).
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Table  1  Causes  and  results  of  endovascular  treatment
for  massive  hemoptysis  managed  in  our  center  over
10  years  (unpublished  data).
Causes  Number  of
patients  (n)
Success,
n  (%)
Tuberculosis  (active
and  late
complications)
189  158  (84)
Bronchiectasis  159  126  (79)
Cancer  149  91  (61)
Cryptogenic  126  106  (84)
Aspergilloma  48  21  (44)
Chronic  obstructive
pulmonary  disease
29  19  (66)
Other  67  48  (72)
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aSevere  hemoptysis:  From  diagnosis  to  embolization  
proximal  hilar)  should  be  avoided  as  there  is  a  highly  devel-
oped  anastomotic  network  in  the  mediastinal  and  proximal
region  of  the  hilum  of  the  lung  (Fig.  3e,  f).  If  occluded  proxi-
mally,  this  anastomotic  network  can  revascularize  the  vessel
distal  to  the  occlusion,  making  embolization  less  effective
or  even  hazardous  by  closing  a  recognized  and  straightfor-
ward  embolization  approach.  Coils  should  be  reserved  for
permanent  very  distal  obstruction,  or  if  catheterization  is
difﬁcult  and/or  hazardous  (Fig.  9).  The  other  embolization
materials  should  be  considered  in  occasional  cases  and  need
to  be  understood  in  advance  of  their  use,  in  the  same  way
as  the  liquids  (Onyx®,  Histoacryle®,  etc.).
Pulmonary artery vascular occlusion
In  most  situations,  the  approach  via  the  right  femoral  vein
is  sufﬁcient,  using  a  7-  or  8-French  introducer.  In  speciﬁc
situations,  such  as  a  raised  right  hemidiaphragm  and  a  past
history  of  right  middle  and  lower  lobe  lobectomies,  the
internal  jugular  approach  is  preferred  for  anatomical  rea-
sons.  A  guide  catheter  is  highly  recommended  or  may  even
be  essential  for  at  least  three  reasons:  catheterization,
changing  catheters  and  optimal  occlusion  of  the  target  pul-
monary  artery.  The  pulmonary  arteries  are  wide  and  far  from
the  puncture  site  with  at  least  2  curves  before  reaching  the
target,  making  direct  catheterization  difﬁcult.  The  use  of
a  guide  catheter  helps  to  lead  the  catheter  (coaxial)  using
the  double  curve  (the  curve  of  the  guide  catheter  and  the
curve  of  the  coaxial  catheter).  Changing  catheter  is  more
straightforward  with  a  guide  catheter  and  in  addition  when
occlusion  is  achieved  using  coils,  the  guide  catheter  offers
two  additional  merits  of  compacting  the  coil  and  preventing
pullback  of  the  catheter,  avoiding  accidental  occlusion  of
off-target  arteries.
The  occlusion  should  be  as  close  as  possible  to  the
pulmonary  artery  lesion  responsible  for  the  bleeding.  Ide-
ally,  for  a  pulmonary  artery  pseudoaneurysm,  the  occlusion
should  be  made  proximal  and  distal  to  the  aneurysm,
although  this  carries  an  increased  risk  of  iatrogenic  rup-
ture.  Proximal  occlusion  is  sufﬁcient  for  a  distal,  acute
rapid  process  or  in  cancer.  Conversely,  in  inﬂammatory  and
chronic  infectious  processes,  particularly  tuberculosis,  sand-
wich  occlusion  is  preferable  in  order  to  avoid  the  recurrence
of  the  bleeding  through  the  systemic  vessels.  The  aim  is  to
produce  occlusion  at  the  tip  of  the  catheter  without  the
need  for  distal  embolization.  Attention  should  be  paid  to
the  risk  of  rupturing  a  pseudoaneurysm  during  high-pressure
injection  or  when  a  coil  or  plug  is  deployed  in  an  irregular
artery  surrounded  by  necrosis.  In  decreasing  order  of  fre-
quency,  the  occlusion  materials  most  often  used  are  coils,
plugs  (vascular  plug  or  microvascular  plug),  graft  stents  and
Onyx®.  The  graft  stent  should  be  used  for  localized  lesions
when  the  artery  has  to  be  kept  patent.
Results and  complications
Bronchial  artery  embolization  provides  immediate  control
(Table  1)  of  hemoptysis  in  over  80%  of  cases  (65  to  92%)
depending  on  the  underlying  disease  [6,17,18].  Control  is
more  effective  with  cryptogenic  hemoptysis,  bronchiecta-
sis  or  active  tuberculosis  whereas  this  is  less  effective  in
aspergillosis  or  lung  cancer.  If  an  early  recurrence  occurs
h
e
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iTotal  767  569  (74)
10  to  20%  of  cases),  the  immediate  response  should  be
 further  review  of  the  MDCTA  looking  for  other  bronchial
ystemic  arterial  conditions,  either  of  atypical  origin,  or
ctopic,  a  NBSA  supplying  the  territory  responsible  for  the
leed  or  alternatively  a  pulmonary  source  which  was  not
nitially  seen.  The  use  of  systemic  vasoconstrictors  medica-
ion  before  bronchial  artery  embolization  or  of  resorbable
ragments  (Gelfoam)  during  embolization  is  also  a  possible
ource  of  recurrence.  In  most  cases  a  second  angiography
Fig.  7h,  i)  usually  enables  the  bleeding  to  be  controlled
gain.
Long-term  recurrence  after  bronchial  arterial  emboliza-
ion  occurs  in  10  to  60%  of  cases  and  is  due  either
o  recanalization  of  the  embolized  vessels  or  to  further
ypervascularization  when  the  cause  of  hypervasculariza-
ion  remains.  This  is  common  in  aspergilloma  and  cancer
17,19,20].
The  major  complications  of  embolization  are  rare  but
erious  and  predominantly  involve  accidental  embolization
f  the  median  anterior  spinal  artery  which  gives  rise  to
he  right  and  left  superior  intercostal  arteries  and  are
esponsible  for  serious  neurological  events  (Brown-Sequard
yndrome  and  paraplegia)  with  an  estimated  incidence  of
.6  to  6.5%  [18]. The  other  complications  are  necrosis  of
he  esophageal  or  bronchial  walls,  myocardial  infarction
r  more  systemic  spread  because  of  an  unstable  catheter
eading  to  reﬂux  of  the  embolization  materials  into  the
orta  (ischemic  stroke,  gastrointestinal  infarction,  splenic
ematoma,  etc.).  The  possibility  of  splenic  infarction  should
e  investigated  if  a  patient  develops  abdominal  pain  pre-
ominantly  in  the  left  hypochondrium  together  with  shock
nd  a  fall  in  hemoglobin  [21]. There  is  a  risk  of  acute  dis-
al  ischemia  at  the  arterial  puncture  site  in  patients  with
therosclerosis  as  a  result  of  thrombosis  (partly  predisposed
o  by  the  length  of  the  procedure  and  multiple  angiogra-
hy  sessions  for  recurrences  with  several  punctures).  The
ncidence  of  these  episodes  is  greatly  inﬂuenced  by  oper-
tor  experience  [18,22]  and  some  can  be  avoided  by  using
yperselective  microcatheters,  which  in  expert  hands  allow
mbolization  beyond  the  origin  of  an  esophageal  branch  or
nto  a  right  bronchial  artery  well  beyond  the  origin  of  the
ntercostal  artery  which  may  give  rise  to  a  median  anterior
7 A.  Khalil  et  al.
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• Serious  complications  are  rare  (less  than  5%  in
trained  hands):  cerebrovascular  accident,  spinal
ischemia  or  esophageal  necrosis.
• Early  recurrence  (10  to  20%):  review  the  mechanism
of  the  hemoptysis  on  MDCTA,  further  embolization
(unembolized  collateral,  incomplete  embolization  of
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CRP  were  raised.  A  MDCTA  was  performed  (Figs.  11—14).
Figure 11. Axial views of a MDCTA in the parenchymal window.86  
pinal  artery  in  patients  with  a  right  broncho-intercostal
runk  or  during  unstable  catheterization.  The  most  common
omplications  of  embolization  are  transient  chest  pain.
onclusion
DCTA  has  become  an  unquestioned  investigation  in  the
retreatment  assessment  of  massive  hemoptysis.  It  enables
erfect  visualization  of  the  bronchopulmonary  vascular  tree
nd  mechanisms  responsible  for  severe  hemoptysis.  The  ﬁrst
ine  treatment  in  the  acute  phase  and  in  inoperative  patients
s  endovascular.
Take-home  messages
General  concepts
• Hemoptysis:  blood  arising  from  the  infraglottic
region.
• Hemoptysis,  symptom  (less  than  50  mL/24—48  h):
alarm  signal  for  investigation  into  the  cause.
• Hemoptysis,  disease  (serious)  (volume  over  200  mL/
24—48  h):  life  threatening  requires  emergency
speciﬁc  treatment.
The  use  of  multidetector  CT-angiography
• Technique:  optimal  enhancement  of  all  intra-
thoracic  vascular  structures.
• Assesses  the  severity  of  the  hemoptysis.
• Site  of  the  bleeding:  ground  glass  opacity  or  localized
lung  consolidation.
• Identiﬁes  the  pulmonary  artery  mechanism  for  the
bleeding  (less  than  10%  of  hemoptysis):  necrosis,
pseudoaneurysm,  irregular  pulmonary  artery  in  the
wall  of  a  cavity  or  necrosis.
• Complete  mapping  of  the  bronchial  and  non-
bronchial  systemic  arteries  (over  90%  of  hemoptysis).
• Identiﬁes  the  cause  of  the  bleeding:  tuberculosis,
bronchiectasis,  lung  cancer  (2/3  of  causes).  No  cause
found  (cryptogenic  hemoptysis)  in  20  to  30%  of  cases.
Endovascular  treatment
• Management  in  a  specialized  unit:  intensive  care  and
interventional  radiology  ±  thoracic  surgery.
• Indication:  at  least  one  of  the  following  criteria:
respiratory  tolerance  (acute  respiratory  failure),
pulmonary  arterial  mechanism  and  hemoptysis  of
over  200  mL/24—48  h.
• The  approach  (femoral  artery  or  vein)  depends  on
MDCTA  ﬁndings.
• Embolization  material:  particularly  microparticles
(over  500  microns).
• The  median  anterior  spinal  artery  (arising  from  the
intercostal  artery)  must  be  looked  for  routinely  and
speciﬁcally  during  opaciﬁcation  of  the  right  broncho-
intercostal  trunk;  if  it  is  present  or  there  is  a  doubt  as
to  its  presence  the  use  of  particles  is  formally  contra-
indicated  and  these  should  be  replaced  by  occlusion
with  micro-coils.
• Embolization  controls  hemoptysis  in  65  to  92%  of
cases  depending  on  cause.
Fan  artery,  vasoconstrictor  therapy,  etc.).
linical case
his  26-year-old  man  was  referred  for  hemoptysis  of  200  mL
n  one  occasion  12  hours  ago.  Clinical  examination  revealed
 patient  in  good  general  health,  apyrexial  and  without
ecent  weight  loss.  He  had  no  signs  of  respiratory  distress
nd  his  respiratory  rate  was  14/min  with  an  oxygen  satu-
ation  of  98%.  Laboratory  investigations  showed  moderate
icrocytic  anemia.  His  erythrocyte  sedimentation  rate  andigure 12. Axial views of a MDCTA in the mediastinal window.
Severe  hemoptysis:  From  diagnosis  to  embolization  
Figure 13. Axial views of a MDCTA in the parenchymal window
passing through the left atrium.
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with no explainable lesions in computed tomography. RespirFigure 14. Axial views of a MDCTA in the mediastinal window.
Questions
1)  What  is  the  site  of  the  bleeding,  describing  the  side,
lobe  and  segment?  List  the  CT  evidence  supporting  your
answer.
2)  What  is  the  mechanism  of  the  bleeding?
3)  What  is  the  cause  of  the  bleeding,  giving  evidence  sup-
porting  it?
4)  What  are  the  arguments  for  emergency  treatment?
5)  In  the  event  of  endovascular  treatment,  describe  the
approach  route,  type  of  catheters  and  embolization
materials.
Answers
1)  The  site  of  the  bleeding  is  on  the  left,  in  the  culmen  and
speciﬁcally  in  the  anterior  segment  of  the  culmen  (S2).
The  CT-scan  signs  that  localize  the  site  of  bleeding  are
the  lung  consolidation  located  in  segment  S2  on  the  left
(Fig.  11,  asterisk)  combined  with  an  aneurysmal  appear-
ance  in  the  pulmonary  artery  within  the  consolidation
(Fig.  12,  arrow).787
)  The  mechanism  of  the  bleeding  is  the  rupture  of  a
pulmonary  artery  aneurysm  due  to  the  presence  of  an
irregular  widening  (Fig.  12, arrow)  of  the  pulmonary
artery  (A2  left)  within  the  consolidation  (Fig.  11,  aster-
isk).
)  The  cause  of  the  hemoptysis  is  Behc¸et’s disease  or
Hughes-Stovin’s  syndrome.  The  evidence  for  this  is:
•  non-radiological  evidence:
a.  young  person  in  good  general  health  and  apyrexial,
b.  inﬂammatory  syndrome  with  microcytic  anemia
and  increased  erythrocyte  sedimentation  rate  and
CRP  (chronic  inﬂammatory  process);
•  radiological  evidence:
a. the  combination  of  pulmonary  artery  aneurysms
(asterisks)  and  thromboses/inﬂammatory  thickening
of  the  wall  of  these  aneurysms  (arrows)  clearly  visi-
ble  on  Figs.  13  and  14.  The  Hughes-Stovin  syndrome
is  similar  to  Behc¸et’s disease  although  has  no  skin
involvement  (bipolar  aphthosis).  This  is  a  purely  vas-
cular  syndrome  combining  pulmonary  artery  disease
(aneurysms  and  thromboses)  and  thromboses  of  the
large  vessels,  particularly  the  inferior  vena  cava.
)  The  arguments  for  emergency  management  are:
a.  the  hemoptysis  volume  of  200  mL/12  h:  this  is  greater
than  the  criterion  of  200  mL/24—48  h,
b.  the  mechanism  involves  rupture  of  a  pulmonary  artery
aneurysm;  systemic  vasoconstrictor  therapy  is  inef-
fective  on  pulmonary  artery  lesions.
)  The  approach  route:  the  right  femoral  vein.  If  the  inferior
vena  cava  is  thrombosed  the  right  internal  jugular  or  right
basilic  vein  can  be  used.
Type  of  catheter:  the  use  of  a  guide  catheter  is  essen-
tial  to  ensure  navigation  and  optimal  embolization  of  the
pulmonary  arteries.
The  abnormality  to  be  treated:  only  the  aneurysm  in
segment  A2  of  the  left  should  be  treated.  The  other
abnormalities  should  be  treated  medically  (immunosu-
pression  and/or  corticosteroids).  The  other  abnormal-
ities  responded  well  to  this  medical  treatment  in  this
patient.
Embolization  materials:  either  coils  or  a  liquid  material
can  be  used.  In  this  patient,  we  used  Onyx® in  order  to
lose  as  little  lung  parenchyma  as  possible.
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
eferences
[1] Jones R, Latinovic R, Charlton J, Gulliford MC. Alarm symptoms
in early diagnosis of cancer in primary care: cohort study using
General Practice Research Database. BMJ 2007;334:1040.
[2] Lee YJ, Lee S-M, Park JS, Yim J-J, Yang S-C, Kim YW, et al. The
clinical implications of bronchoscopy in hemoptysis patientsMed 2012;106:413—9.
[3] Corey R, Hla KM. Major and massive hemoptysis: reassessment
of conservative management. Am J Med Sci 1987;294:301—9.
7[
[
[
[
[
[
[
[
[
[
[
[88  
[4] Patel U, Pattison CW, Raphael M. Management of massive
haemoptysis. Br J Hosp Med 1994;52:74—8.
[5] Fartoukh M, Khoshnood B, Parrot A, Khalil A, Carette M-F, Sto-
clin A, et al. Early prediction of in-hospital mortality of patients
with hemoptysis: an approach to deﬁning severe hemoptysis.
Respir Int Rev Thorac Dis 2012;83:106—14.
[6] Fartoukh M, Khalil A, Louis L, Carette M-F, Bazelly B, Cadranel
J, et al. An integrated approach to diagnosis and management
of severe haemoptysis in patients admitted to the intensive
care unit: a case series from a referral centre. Respir Res
2007;8:11.
[7] Chalumeau-Lemoine L, Khalil A, Prigent H, Carette M-F, Far-
toukh M, Parrot A. Impact of multidetector CT-angiography on
the emergency management of severe hemoptysis. Eur J Radiol
2013;82:e742—7.
[8] Remy-Jardin M, Bouaziz N, Dumont P, Brillet P-Y, Bruzzi J,
Remy J. Bronchial and non bronchial systemic arteries at multi-
detector row CT angiography: comparison with conventional
angiography. Radiology 2004;233:741—9.
[9] Khalil A, Fartoukh M, Tassart M, Parrot A, Marsault C,
Carette M-F. Role of MDCT in identiﬁcation of the bleeding
site and the vessels causing hemoptysis. Am J Roentgenol
2007;188:W117—25.
10] Khalil A, Soussan M, Mangiapan G, Fartoukh M, Parrot A, Carette
M-F. Utility of high-resolution chest CT scan in the emergency
management of haemoptysis in the intensive care unit: sever-
ity, localization and aetiology. Br J Radiol 2007;80:21—5.
11] Revel MP, Fournier LS, Hennebicque AS, Cuenod CA, Meyer G,
Reynaud P, et al. Can CT replace bronchoscopy in the detec-
tion of the site and cause of bleeding in patients with large or
massive hemoptysis? Am J Roentgenol 2002;179:1217—24.
12] Khalil A, Fartoukh M, Parrot A, Bazelly B, Marsault C, Carette M-
F. Impact of MDCT angiography on the management of patients
with hemoptysis. Am J Roentgenol 2010;195:772—8.
[A.  Khalil  et  al.
13] Khalil A, Parrot A, Nedelcu C, Fartoukh M, Marsault C,
Carette M-F. Severe hemoptysis of pulmonary arterial origin:
signs and role of multidetector row CT angiography. Chest
2008;133:212—9.
14] Hartmann IJC, Remy-Jardin M, Menchini L, Teisseire A, Khalil
C, Remy J. Ectopic origin of bronchial arteries: assess-
ment with multidetector helical CT angiography. Eur Radiol
2007;17:1943—53.
15] Yoon YC, Lee KS, Jeong YJ, Shin SW, Chung MJ, Kwon OJ.
Hemoptysis: bronchial and nonbronchial systemic arteries at
16-detector row CT. Radiology 2005;234:292—8.
16] Yoon W, Kim YH, Kim JK, Kim YC, Park JG, Kang HK. Massive
hemoptysis: prediction of nonbronchial systemic arterial sup-
ply with chest CT. Radiology 2003;227:232—8.
17] Chun J-Y, Belli A-M. Immediate and long-term outcomes
of bronchial and non-bronchial systemic artery embolization
for the management of haemoptysis. Eur Radiol 2010;20:
558—65.
18] Mal H, Rullon I, Mellot F, Brugière O, Sleiman C, Menu
Y, et al. Immediate and long-term results of bronchial
artery embolization for life-threatening hemoptysis. Chest
1999;115:996—1001.
19] Katoh O, Kishikawa T, Yamada H, Matsumoto S, Kudo S. Recur-
rent bleeding after arterial embolization in patients with
hemoptysis. Chest 1990;97:541—6.
20] Kim YG, Yoon H-K, Ko GY, Lim C-M, Kim WD, Koh Y. Long-term
effect of bronchial artery embolization in Korean patients with
haemoptysis. Respirol Carlton Vic 2006;11:776—81.
21] Labbe V, Roques S, Boughdène F, Razazi K, Khalil A,
Parrot A, et al. Shock complicating successful bronchial
artery embolization for severe hemoptysis. Chest 2009;135:
215—7.
22] Wong ML, Szkup P, Hopley MJ. Percutaneous embolotherapy for
life-threatening hemoptysis. Chest 2002;121:95—102.
